Cipla Ltd logo

Cipla Ltd

CIPLA NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
1.2L Cr
Volatility
Moderate
P/E Ratio
34.29
EBITDA
₹6,765 Cr
Return on Equity
11.21%
Debt to Equity
0.02
Book Value
₹426.22
EPS
₹55.04
52W High
₹1,673
52W Low
₹1,165.7

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Cipla Ltd insights

57 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Weaknesses

2
  • The company has delivered a poor sales growth of 8.01% over past five years.
  • Promoter holding has decreased over last 3 years: -4.24%

Growth Rate

Revenue Growth
2.24% ↘
Net Income Growth
-26.86% ↘
Cash Flow Change
-21.28% ↘
ROE
-33.71% ↘
ROCE
-31.02% ↘
EBITDA Margin (Avg.)
-17.18% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Cipla Ltd is a ₹1.18 lakh crore pharma company that achieved its highest-ever annual revenue of ₹28,163 crore in FY26 (up 2% YoY), but saw annual PAT decline 26% to ₹3,879 crore as EBITDA margin compressed from 25.9% to 21%. The company remains nearly debt-free with a 10-year profit CAGR of 11%, though near-term earnings have deteriorated sharply with TTM profit declining 34%.

Bull Case 8
  • Company is almost debt-free, providing financial flexibility and resilience during downturns
  • Achieved highest-ever annual revenue of ₹28,163 crore in FY26, demonstrating topline durability
  • 10-year compounded profit growth of 11% CAGR shows long-term earnings compounding ability
  • Healthy dividend payout ratio of 25.7% with current yield of 0.89%, declared ₹16/share dividend in FY25
  • One-India business grew 10% YoY in Q3 FY26 with chronic therapy mix improving to 62.3%, indicating portfolio quality
  • North America business delivered $167 million quarterly revenue in Q3 FY26, maintaining scale in the US generics market
  • 3-year ROE of 15% and 5-year ROE of 14% reflect consistent capital efficiency over medium term
  • One-Africa business grew 14% YoY in Q4 FY26 and 7% for full year, providing geographic diversification
Bear Case 8
  • FY26 annual PAT declined 26% YoY to ₹3,879 crore from ₹5,273 crore, a significant earnings deterioration
  • EBITDA margin contracted sharply from 25.9% in FY25 to 21% in FY26, indicating cost or pricing pressures
  • Q4 FY26 profit fell 55% YoY to ₹555 crore, showing accelerating quarterly earnings decline
  • TTM compounded profit growth stands at -34%, the worst among recent periods
  • Sales growth of only 2% TTM and 8% over 5 years is modest for a company trading at PE of 35.2x
  • Promoter holding has decreased by 4.26% over the last 3 years, with combined promoter stake falling to ~29.2%
  • Stock has delivered -6% return over 1 year, underperforming broader market indices
  • Negligible contribution from gRevlimid in recent quarters removes a key US profit driver going forward

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Headwinds 3
  • Q1 PAT drops 39% YoY Jul 24

    Cipla's Q1FY27 net profit fell 39.2% to ₹785.55 crore due to margin contraction and labour code-related costs. EBITDA margin contracted to 16.7% versus guidance of 18-20%.

  • NSE lowers ESG score Aug 11

    NSE lowered Cipla's ESG score to 67 for FY26, citing a product recall by its US subsidiary.

  • Indore facility reinspection pending Jul 23

    Cipla anticipates an upcoming reinspection of its Indore manufacturing facility, which could impact US product approvals if issues are found.

Positives 4
  • FDA nod for generic Advair Diskus Jul 27

    Cipla received US FDA approval for generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three strengths, targeting a ~$908 million US market.

  • Record One India quarterly revenue Jul 24

    One India business posted record quarterly revenue of ₹3,452 crore in Q1FY27, driving overall revenue to a record ₹7,119 crore (up 2.3% YoY).

  • GLP-1 domestic market opportunity Jul 21

    Semaglutide patent expiry in India in March enables Cipla to enter the GLP-1 generic segment, expected to provide meaningful lift to domestic business.

  • FY27 margin guidance reaffirmed Jul 23

    Cipla reaffirmed its FY27 EBITDA margin forecast of 18-20% during its Q1 concall, alongside plans for four new product launches.

Neutral 5
  • ₹58 Cr block trade on BSE Aug 4

    A block trade of ~400,000 shares was executed at ₹1,458 per share on the BSE block deal window, totalling ₹58.32 crore.

  • SES raises ESG score to 69.9 Aug 11

    SES raised Cipla's ESG score to 69.9 for FY26, partially offsetting the NSE downgrade.

  • New Global CFO appointed Jul 23

    Cipla appointed Dinesh Jain as Global CFO and KMP effective July 24, 2026, succeeding Ashish Adukia who moves to a business leadership role.

  • Q1FY27 earnings call posted Jul 23

    Cipla made the audio recording of its Q1FY27 earnings conference call available on its website as disclosed to exchanges.

  • Senior executive reporting change Jul 23

    Sanjay Joseph, Head of API Business, ceased to be Senior Managerial Personnel effective July 24, 2026 due to reporting structure change.

TL;DR: Cipla delivered record Q1FY27 revenue of ₹7,119 crore led by strong India business, but profitability took a significant hit with PAT down 39% and EBITDA margins compressing to 16.7%. The US FDA approval for generic Advair Diskus (~$908M market) and GLP-1 domestic opportunity are meaningful growth catalysts. Key risks include margin recovery execution, the pending Indore reinspection, and the US product recall flagged by NSE. The trend is mixed near-term on margins but improving on revenue drivers, with FY27 guidance of 18-20% EBITDA margins suggesting management expects a recovery in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
6,329
6,678
6,604
6,163
6,694
7,051
7,073
6,730
6,957
7,589
7,074
6,541
7,119
Expenses
4,835
4,944
4,856
4,847
4,978
5,165
5,084
5,192
5,179
5,695
5,819
5,586
5,927
Operating Profit
1,494
1,734
1,748
1,316
1,716
1,886
1,989
1,538
1,778
1,895
1,255
955
1,192
OPM %
24%
26%
26%
21%
26%
27%
28%
23%
26%
25%
18%
15%
17%
Other Income
136
176
-10
249
160
191
222
289
259
269
-70
148
211
Interest
16
26
30
18
18
15
15
14
14
13
14
13
17
Depreciation
239
290
233
288
247
272
280
309
253
297
278
383
304
PBT
1,375
1,594
1,474
1,259
1,611
1,789
1,916
1,504
1,770
1,854
893
707
1,082
Tax %
28%
28%
28%
26%
27%
27%
17%
19%
27%
27%
24%
22%
27%
Net Profit
998
1,155
1,068
932
1,175
1,305
1,575
1,214
1,292
1,353
674
543
786
EPS in Rs
12.33
14.01
13.08
11.63
14.58
16.13
19.45
15.13
16.06
16.73
8.37
6.87
9.77
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
11,345
13,790
14,394
15,156
16,362
17,132
19,160
21,763
22,753
25,774
27,548
28,163
28,324
Expenses
9,183
11,310
11,898
12,329
13,265
13,926
14,907
17,211
17,726
19,483
20,420
22,280
23,027
Operating Profit
2,163
2,480
2,496
2,826
3,097
3,206
4,252
4,553
5,027
6,291
7,128
5,883
5,297
OPM %
19%
18%
17%
19%
19%
19%
22%
21%
22%
24%
26%
21%
19%
Other Income
164
208
208
280
477
344
266
99
293
552
862
606
558
Interest
168
207
159
114
168
197
161
106
110
90
62
54
57
Depreciation
505
754
1,323
1,323
1,326
1,175
1,068
1,052
1,172
1,051
1,107
1,211
1,262
PBT
1,654
1,727
1,222
1,669
2,079
2,178
3,290
3,493
4,038
5,702
6,821
5,224
4,536
Tax %
24%
19%
15%
15%
27%
29%
27%
27%
30%
27%
22%
26%
—
Net Profit
1,229
1,383
1,035
1,417
1,492
1,500
2,389
2,547
2,833
4,154
5,269
3,862
3,356
EPS in Rs
14.71
16.93
12.51
17.52
18.96
19.18
29.82
31.19
34.71
51.05
65.28
48.02
41.74
Div. Payout %
14%
12%
16%
17%
16%
21%
17%
16%
24%
25%
25%
27%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
161
161
161
161
161
161
161
161
161
161
162
162
Reserves
10,641
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
31,032
34,270
Borrowings
1,703
5,202
4,113
4,098
4,316
2,816
2,014
1,056
803
559
438
614
Other Liabilities
3,166
4,331
4,213
4,346
4,433
4,843
4,514
4,960
5,089
5,267
5,702
7,297
Total Liabilities
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343
Fixed Assets
6,830
9,368
9,492
9,950
9,608
9,683
9,516
9,683
9,160
9,607
10,006
12,434
CWIP
581
2,061
1,683
981
676
825
969
766
1,093
1,153
1,566
2,042
Investments
640
759
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
7,933
8,223
Other Assets
7,620
8,862
8,721
10,483
10,923
11,444
11,661
13,857
15,384
16,323
17,828
19,643
Total Assets
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
5,005
3,940
Investing
-950
-4,533
-1,304
-834
-1,688
114
-2,374
-1,858
-2,376
-2,982
-3,682
-2,234
Financing
165
3,104
-1,326
-385
-349
-2,949
-1,240
-1,600
-958
-1,200
-1,293
-1,234
Net Cash Flow
388
312
-248
243
-345
234
141
-132
-97
-49
30
473
Free Cash Flow
548
688
1,284
723
1,187
2,083
2,964
2,645
2,102
2,819
3,490
928
CFO/OP
72
91
113
77
74
122
113
98
90
91
94
94
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
62
65
75
93
83
66
57
65
68
73
73
Inventory Days
329
273
239
271
250
267
232
230
228
217
231
252
Days Payable
126
106
108
142
123
139
103
108
112
102
116
123
Cash Conversion Cycle
267
230
196
204
220
211
195
180
181
182
188
202
Working Capital Days
89
-10
99
118
132
113
94
95
113
120
128
106
ROCE %
15%
13%
7%
9%
11%
12%
17%
17%
18%
23%
23%
15%

Shareholding Pattern

As of Jun 2026
DIIs 34.63%
Promoters 29.21%
FIIs 20.21%
Public 13.74%
Others 2.20%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
36.73%
36.72%
36.12%
36.11%
33.63%
33.61%
33.61%
33.61%
33.55%
33.47%
33.47%
33.47%
33.47%
30.91%
30.92%
29.19%
29.20%
29.19%
29.21%
29.21%
29.21%
29.21%
FIIs
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.00%
0.00%
0.00%
25.74%
25.73%
25.83%
27.81%
28.80%
26.65%
26.28%
25.25%
24.55%
23.93%
22.56%
20.21%
DIIs
16.79%
15.91%
17.41%
17.61%
17.72%
17.12%
19.71%
21.13%
22.10%
24.34%
24.18%
24.33%
24.42%
24.95%
24.16%
27.71%
28.15%
29.26%
30.25%
30.72%
31.97%
34.63%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
16.24%
16.14%
16.01%
15.97%
15.55%
15.41%
14.83%
14.72%
14.85%
14.66%
14.45%
14.34%
14.20%
14.24%
14.16%
14.29%
14.13%
14.10%
13.82%
13.84%
13.98%
13.74%
Others
30.23%
31.22%
30.47%
30.30%
33.10%
33.86%
31.84%
30.53%
29.50%
27.53%
2.16%
2.12%
2.08%
2.09%
1.95%
2.15%
2.23%
2.20%
2.16%
2.29%
2.28%
2.20%
No. of Shareholders
3,64,796
4,08,401
4,10,831
4,51,365
4,18,584
4,18,910
3,88,864
4,04,182
4,75,293
4,66,513
4,26,861
4,25,731
4,36,154
4,63,569
4,70,234
5,25,114
5,43,420
5,49,655
5,34,587
5,40,521
5,84,217
5,78,679

Documents

1
Concall - May 2017 May 2017
2
Concall - May 2017 May 2017
3
Concall - Aug 2017 Aug 2017
4
Concall - Nov 2017 Nov 2017
5
Concall - Feb 2018 Feb 2018

Frequently Asked Questions about Cipla Ltd

What does Cipla Ltd do?
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
Where is Cipla Ltd (CIPLA) listed?
Cipla Ltd is listed on the Indian stock exchanges. It is listed on NSE: CIPLA and BSE: 500087. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Cipla Ltd belong to?
Cipla Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Cipla Ltd?
Cipla Ltd has a market capitalisation of approximately ₹115853.10 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Cipla Ltd?
The Price-to-Earnings (PE) ratio of Cipla Ltd is 34.29. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Cipla Ltd?
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.7 and a high of ₹1,673. This range helps investors understand the stock's price volatility and recent trading levels.
Does Cipla Ltd pay dividends?
Yes, Cipla Ltd has a dividend yield of 0.91%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Cipla Ltd?
Cipla Ltd has a Return on Equity (ROE) of 11.21%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Cipla Ltd on Tapetide?
On Tapetide, you can view Cipla Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Website cipla.com
CEO Mr. Umang Vohra B.E., M.B.A.
Employees 30,313
Listed 1995-02-08
Face Value ₹ 2
Issued Size 80,77,71,798

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List